» Articles » PMID: 38136203

Oxidative Stress Induced by Lipotoxicity and Renal Hypoxia in Diabetic Kidney Disease and Possible Therapeutic Interventions: Targeting the Lipid Metabolism and Hypoxia

Overview
Date 2023 Dec 23
PMID 38136203
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress, a hallmark pathophysiological feature in diabetic kidney disease (DKD), arises from the intricate interplay between pro-oxidants and anti-oxidants. While hyperglycemia has been well established as a key contributor, lipotoxicity emerges as a significant instigator of oxidative stress. Lipotoxicity encompasses the accumulation of lipid intermediates, culminating in cellular dysfunction and cell death. However, the mechanisms underlying lipotoxic kidney injury in DKD still require further investigation. The key role of cell metabolism in the maintenance of cell viability and integrity in the kidney is of paramount importance to maintain proper renal function. Recently, dysfunction in energy metabolism, resulting from an imbalance in oxygen levels in the diabetic condition, may be the primary pathophysiologic pathway driving DKD. Therefore, we aim to shed light on the pivotal role of oxidative stress related to lipotoxicity and renal hypoxia in the initiation and progression of DKD. Multifaceted mechanisms underlying lipotoxicity, including oxidative stress with mitochondrial dysfunction, endoplasmic reticulum stress activated by the unfolded protein response pathway, pro-inflammation, and impaired autophagy, are delineated here. Also, we explore potential therapeutic interventions for DKD, targeting lipotoxicity- and hypoxia-induced oxidative stress. These interventions focus on ameliorating the molecular pathways of lipid accumulation within the kidney and enhancing renal metabolism in the face of lipid overload or ameliorating subsequent oxidative stress. This review highlights the significance of lipotoxicity, renal hypoxia-induced oxidative stress, and its potential for therapeutic intervention in DKD.

Citing Articles

Isorhamnetin Ameliorates Non-Esterified Fatty Acid-Induced Apoptosis, Lipid Accumulation, and Oxidative Stress in Bovine Endometrial Epithelial Cells via Inhibiting the MAPK Signaling Pathway.

Lv H, Liu L, Zou W, Yang Y, Li Y, Yang S Antioxidants (Basel). 2025; 14(2).

PMID: 40002343 PMC: 11852151. DOI: 10.3390/antiox14020156.


Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.

Zhang Y, Ou G, Peng L, Pan J, Zhang S, Shi J Front Endocrinol (Lausanne). 2025; 15:1434145.

PMID: 39877840 PMC: 11772207. DOI: 10.3389/fendo.2024.1434145.


Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage.

Jang K, Hur J, Lee D, Kim S Biomedicines. 2025; 12(12.

PMID: 39767613 PMC: 11673429. DOI: 10.3390/biomedicines12122706.


β-cryptoxanthin suppresses oxidative stress via activation of the Nrf2/HO-1 signaling pathway in diabetic kidney disease.

Ke J, Zang H, Liu Y, Teng Q, Hua J, Peng D Front Pharmacol. 2024; 15:1480629.

PMID: 39619612 PMC: 11604467. DOI: 10.3389/fphar.2024.1480629.


Learning from Negative Trials for Diabetic Kidney Disease.

Touyz R J Am Soc Nephrol. 2024; 35(11):1463-1465.

PMID: 39325537 PMC: 11543022. DOI: 10.1681/ASN.0000000511.


References
1.
Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T . Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018; 9(5):1025-1032. PMC: 6123054. DOI: 10.1111/jdi.12802. View

2.
Cao S, Kaufman R . Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal. 2014; 21(3):396-413. PMC: 4076992. DOI: 10.1089/ars.2014.5851. View

3.
Park M, Han H, Kim D . Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress. Int J Mol Sci. 2017; 18(7). PMC: 5535913. DOI: 10.3390/ijms18071421. View

4.
Kaushal G, Chandrashekar K, Juncos L . Molecular Interactions Between Reactive Oxygen Species and Autophagy in Kidney Disease. Int J Mol Sci. 2019; 20(15). PMC: 6696055. DOI: 10.3390/ijms20153791. View

5.
Maxwell P, Eckardt K . HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2015; 12(3):157-68. DOI: 10.1038/nrneph.2015.193. View